Table 3.

Research Recommendations: Clinical Features

1.	Evaluating puff topography, breath holding, or bearing down via questionnaires, interviews, and assessment of vaping techniques in the laboratory setting may clarify the role of vaping styles in disease pathogenesis.
2.	Generation of more specific criteria for the diagnosis of EVALI is needed to differentiate between EVALI and other lung diseases caused by vaping.
3.	A definition of disease severity may help guide clinical research studies of EVALI, such as an O2 requirement of ≥6 L/min for severe, 1–5 L/min for moderate, and no O2 requirement in mild cases.
4.	Classification of both duration of symptoms and disease severity may help identify risk factors for different severities and uncover whether different disease presentations represent a continuum of one disease or represent variants of the disease.
5.	Conducting translational research studies on biospecimens obtained from subjects with EVALI, across different time points and severities of disease, to define the cell types, phenotypes, and molecular pathways involved may yield critical data regarding mechanisms of injury and inflammation.
6.	Developing an EVALI animal model would give insight into disease mechanisms and allow for rapid testing of potential therapeutic agents.
7.	Research is needed related to addiction relapse prevention.
8.	Longitudinal studies in confirmed cases to define the mortality and short- and long-term morbidity for these patients is an important research need.

Definition of abbreviation: EVALI = e-cigarette or vaping product use–associated lung injury.